相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial
J. O'Shaughnessy et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer.
S Vukelja et al.
CANCER RESEARCH (2010)
Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor: phase 2 results in patients with advanced HER2+ breast cancer.
HJ Burstein et al.
CANCER RESEARCH (2010)
Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined
E. D. Saad et al.
ANNALS OF ONCOLOGY (2009)
Effects of Food on Bioavailability of Lapatinib: Useful Data, Wrong Conclusion
Ian F. Tannock
JOURNAL OF CLINICAL ONCOLOGY (2009)
Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer
B. Sherrill et al.
BRITISH JOURNAL OF CANCER (2008)
Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007
Nicholas Wilcken et al.
EUROPEAN JOURNAL OF CANCER (2008)
Progression-free survival as a surrogate endpoint in advanced breast cancer
Rebecca A. Miksad et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2008)
Do clinical practice guidelines (CPGs) change clinical practice? An analysis of CPG impact on referral and treatment patterns for neoadjuvant chemotherapy in bladder cancer
B. J. Miles et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer
Tomasz Burzykowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Progression-free survival is a surrogate for survival in advanced colorectal cancer
Marc Buyse et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment
Eva S. Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Investigation of tumor biomarkers as response predictors in a monotherapy study with lapatinib (L) as a first line treatment in ErbB2 amplified women with breast cancer
H. L. Gomez et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer
Vernon Harvey et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Goals of treatment for patients with metastatic breast cancer
I Smith
SEMINARS IN ONCOLOGY (2006)
Monoclonal antibody-based targeted therapy in breast cancer: Current status and future directions
Chantal Bernard-Marty et al.
DRUGS (2006)
Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer
A Hackshaw et al.
BRITISH JOURNAL OF CANCER (2005)
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:: The M77001 study group
M Marty et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer:: National Cancer Institute of Canada Clinical Trials Group Study MA.19
L Reyno et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women:: Analysis of survival and update of efficacy from the international letrozole breast cancer group
H Mouridsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: A critical assessment based on recently reported phase III trials in colorectal and breast cancer
A Di Leo et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
End points and United States food and drug administration approval of oncology drugs
JR Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: Final results of a phase III study with a factorial design
A Berruti et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results
P Pacini et al.
EUROPEAN JOURNAL OF CANCER (2000)
分享论文
